Bank of New York Mellon Corp cut its stake in shares of ChemoCentryx, Inc. (NASDAQ:CCXI) by 1.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 107,625 shares of the biopharmaceutical company’s stock after selling 1,373 shares during the period. Bank of New York Mellon Corp owned about 0.22% of ChemoCentryx worth $784,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. American Century Companies Inc. acquired a new stake in shares of ChemoCentryx during the first quarter worth $297,000. Teachers Advisors LLC raised its stake in shares of ChemoCentryx by 8.4% in the fourth quarter. Teachers Advisors LLC now owns 40,288 shares of the biopharmaceutical company’s stock worth $298,000 after buying an additional 3,114 shares during the last quarter. Strs Ohio raised its stake in shares of ChemoCentryx by 19.0% in the first quarter. Strs Ohio now owns 52,600 shares of the biopharmaceutical company’s stock worth $382,000 after buying an additional 8,400 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of ChemoCentryx during the fourth quarter worth $483,000. Finally, Adams Diversified Equity Fund Inc. raised its stake in shares of ChemoCentryx by 2.8% in the first quarter. Adams Diversified Equity Fund Inc. now owns 87,900 shares of the biopharmaceutical company’s stock worth $640,000 after buying an additional 2,400 shares during the last quarter. Institutional investors own 49.57% of the company’s stock.
Shares of ChemoCentryx, Inc. (CCXI) traded down 2.7463% on Friday, hitting $7.2065. The stock had a trading volume of 428,690 shares. ChemoCentryx, Inc. has a one year low of $4.06 and a one year high of $10.80. The firm’s 50-day moving average is $9.61 and its 200-day moving average is $7.71. The company’s market cap is $351.00 million.
ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. The firm had revenue of $8.94 million during the quarter. On average, analysts expect that ChemoCentryx, Inc. will post ($0.90) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Bank of New York Mellon Corp Has $784,000 Stake in ChemoCentryx, Inc. (CCXI)” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.com-unik.info/2017/08/11/bank-of-new-york-mellon-corp-decreases-position-in-chemocentryx-inc-ccxi-updated.html.
CCXI has been the topic of a number of recent research reports. Zacks Investment Research upgraded ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Monday, July 17th. Cowen and Company reiterated a “hold” rating on shares of ChemoCentryx in a research report on Tuesday. Finally, BidaskClub downgraded ChemoCentryx from a “strong-buy” rating to a “buy” rating in a report on Thursday.
In related news, insider Petrus Bekker sold 19,877 shares of the stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $9.30, for a total value of $184,856.10. Following the completion of the sale, the insider now owns 79,426 shares in the company, valued at $738,661.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 223,649 shares of company stock worth $2,157,360. 26.80% of the stock is currently owned by company insiders.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
What are top analysts saying about ChemoCentryx Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ChemoCentryx Inc. and related companies.